<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The objective of this Phase 4, open-label, multicentre, observational study was to fulfil food and drug administration (FDA) postapproval requirement to evaluate in healthcare practices the risk of insulin-induced severe <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> following initiation of pramlintide therapy in N = 1297 patients with type 1 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T1DM) and type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> (T2DM) with inadequate glycaemic control </plain></SENT>
<SENT sid="1" pm="."><plain>The duration of the study was approximately 6 months </plain></SENT>
<SENT sid="2" pm="."><plain>During the adjustment period (0-3 months), the incidence and event rate of patient-ascertained severe <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> (PASH) were 4.8% and 0.33 events/patient-year in patients with T1DM and 2.8% and 0.19 events/patient-year in patients with T2DM </plain></SENT>
<SENT sid="3" pm="."><plain>During the maintenance period (&gt;3-6 months), the incidence and event rate of PASH declined in patients with T1DM or T2DM </plain></SENT>
<SENT sid="4" pm="."><plain>This study confirms that in healthcare practices, the risk of insulin-induced severe <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> following the initiation of pramlintide is low in patients with T1DM or T2DM </plain></SENT>
</text></document>